Q1 EPS Forecast for Elanco Animal Health Reduced by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a report released on Monday, April 21st. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $0.28 per share for the quarter, down from their prior forecast of $0.29. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.78 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.09 EPS and FY2028 earnings at $1.29 EPS.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $0.08 EPS. The business's revenue was down 1.4% on a year-over-year basis.

Several other research analysts also recently weighed in on ELAN. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Piper Sandler reduced their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. UBS Group dropped their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Barclays lowered their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $8.90 on Wednesday. The firm has a market cap of $4.42 billion, a price-to-earnings ratio of 22.24, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The stock has a fifty day simple moving average of $10.15 and a two-hundred day simple moving average of $11.74. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $18.80.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. CoreCap Advisors LLC purchased a new position in Elanco Animal Health during the fourth quarter worth about $29,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $35,000. NBC Securities Inc. purchased a new position in shares of Elanco Animal Health during the first quarter worth about $40,000. Parallel Advisors LLC increased its position in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.